The Association Between Low-dose Aspirin Intake and Osteoarthritis: a Population-based Cross-sectional Study Based on NHANES

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2024 Oct 24

PMID 39444823

Authors

Binglang Xiong

Cheng Zhang

Xuhan Cao

Ziyan Guo

Zixing Bai

Weidong Sun

Affiliations

Soon will be listed here.

Abstract

Objectives: Low-dose aspirin is widely used as a preventive medication for cardiovascular diseases. However, there is controversy regarding the impact of low-dose aspirin on articular cartilage. The aim of this study is to explore the association between low-dose aspirin intake and osteoarthritis (OA).

Methods: We conducted a cross-sectional study based on the United States population data from the National Health and Nutrition Examination Survey (NHANES) 2011-2018. The investigation of low-dose aspirin intake and the diagnosis of OA was based on self-reporting in questionnaires. Multivariate regression models was used to assess the relationship between low-dose aspirin intake and OA. In addition, subgroup and interaction analysis were performed to assess the robustness of the results.

Results: A total of 12,215 participants were included in this study. Multivariate logistic regression analysis showed that low-dose aspirin use had significantly increased the odds of OA (OR = 1.14; 95% CI: 1.01-1.28; = 0.035). A significant and consistent association of low-dose aspirin intake with OA was still observed in each subgroup stratified by gender, age, and the presence of comorbidities including diabetes, coronary heart disease, hypertension, and stroke. The results illustrated that the relationship between low-dose aspirin intake and OA was stable in all subgroups and had no interaction.

Conclusion: Our study confirmed that low-dose aspirin intake may increase the risk of OA. Attention should be paid to the possibility of joint degenerative changes in patients who take low-dose aspirin chronically. However, further studies are needed to explore the possible mechanisms behind this association.

References

Wang X, Hunter D, Xu J, Ding C . Metabolic triggered inflammation in osteoarthritis. Osteoarthritis Cartilage. 2014; 23(1):22-30. DOI: 10.1016/j.joca.2014.10.002. View

Little C, Hunter D . Post-traumatic osteoarthritis: from mouse models to clinical trials. Nat Rev Rheumatol. 2013; 9(8):485-97. DOI: 10.1038/nrrheum.2013.72. View

Wluka A, Ding C, Wang Y, Jones G, Urquhart D, Cicuttini F . Aspirin is associated with reduced cartilage loss in knee osteoarthritis: Data from a cohort study. Maturitas. 2015; 81(3):394-7. DOI: 10.1016/j.maturitas.2015.04.015. View

Zeng D, Chen Y, Liao Z, Wei G, Huang X, Liang R . Cartilage organoids and osteoarthritis research: a narrative review. Front Bioeng Biotechnol. 2023; 11:1278692. PMC: 10666186. DOI: 10.3389/fbioe.2023.1278692. View

Espinosa E, Murad J, Khasawneh F . Aspirin: pharmacology and clinical applications. Thrombosis. 2011; 2012:173124. PMC: 3236360. DOI: 10.1155/2012/173124. View

Fermor B, Christensen S, Youn I, Cernanec J, Davies C, Weinberg J . Oxygen, nitric oxide and articular cartilage. Eur Cell Mater. 2007; 13:56-65. DOI: 10.22203/ecm.v013a06. View

Bibbins-Domingo K . Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016; 164(12):836-45. DOI: 10.7326/M16-0577. View

Amin A, Attur M, Patel R, Thakker G, Marshall P, Rediske J . Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest. 1997; 99(6):1231-7. PMC: 507937. DOI: 10.1172/JCI119280. View

Chen A, Gupte C, Akhtar K, Smith P, Cobb J . The Global Economic Cost of Osteoarthritis: How the UK Compares. Arthritis. 2012; 2012:698709. PMC: 3467755. DOI: 10.1155/2012/698709. View

10.

Dehmer S, Maciosek M, Flottemesch T, LaFrance A, Whitlock E . Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2016; 164(12):777-86. DOI: 10.7326/M15-2129. View

11.

Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R . The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000; 43(1):103-8. DOI: 10.1002/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C. View

12.

Wang T, He C . Pro-inflammatory cytokines: The link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 2018; 44:38-50. DOI: 10.1016/j.cytogfr.2018.10.002. View

13.

Hybiak J, Broniarek I, Kiryczynski G, Los L, Rosik J, Machaj F . Aspirin and its pleiotropic application. Eur J Pharmacol. 2019; 866:172762. DOI: 10.1016/j.ejphar.2019.172762. View

14.

. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396(10258):1204-1222. PMC: 7567026. DOI: 10.1016/S0140-6736(20)30925-9. View

15.

Bassleer C, Magotteaux J, Geenen V, Malaise M . Effects of meloxicam compared to acetylsalicylic acid in human articular chondrocytes. Pharmacology. 1997; 54(1):49-56. DOI: 10.1159/000139469. View

16.

Davidson K, Barry M, Mangione C, Cabana M, Chelmow D, Coker T . Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2022; 327(16):1577-1584. DOI: 10.1001/jama.2022.4983. View

17.

Eid J, Rood K, Costantine M . Aspirin and Pravastatin for Preeclampsia Prevention in High-Risk Pregnancy. Obstet Gynecol Clin North Am. 2023; 50(1):79-88. DOI: 10.1016/j.ogc.2022.10.005. View

18.

Neogi T, Krasnokutsky S, Pillinger M . Urate and osteoarthritis: Evidence for a reciprocal relationship. Joint Bone Spine. 2018; 86(5):576-582. PMC: 6531371. DOI: 10.1016/j.jbspin.2018.11.002. View

19.

Brandt K, Palmoski M . Effects of salicylates and other nonsteroidal anti-inflammatory drugs on articular cartilage. Am J Med. 1984; 77(1A):65-9. DOI: 10.1016/s0002-9343(84)80021-2. View

20.

Bruyere O, Cooper C, Arden N, Branco J, Brandi M, Herrero-Beaumont G . Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. Drugs Aging. 2015; 32(3):179-87. PMC: 4366553. DOI: 10.1007/s40266-015-0243-3. View